Search

Displaying results 2091 - 2100 of 10000 in total
  1. Drug

    Istiratumab

    go.drugbank.com/drugs/DB15363
    Investigational

    Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).

  2. Drug

    Lobaplatin

    go.drugbank.com/drugs/DB13049
    Investigational

    Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.

  3. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]

  4. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Viltolarsen is a phosphorodiamidate morpholino oligonucleotide (PMO); PMOs are oligonucleotides in which the five-membered ribofuranosyl ring is replaced with a six-membered morpholino ring, and the phosphodiester … [A218171, A218176, A218191] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping, which retains a productive reading frame and results in the

  5. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … in December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis.

  6. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic … It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].

    Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsProducts: Apixaban 1A Pharma 5 mg – Filmtabletten, Apixaban 1A Pharma 2,5 mg – Filmtabletten
  7. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    Perampanel is a noncompetitive AMPA glutamate receptor antagonist. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

  8. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.

  9. Drug

    Bintrafusp alfa

    go.drugbank.com/drugs/DB15387
    Investigational

    Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer

  10. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.